Kafein

Yazarlar

Özge Ertem
M. Aylin Arıcı

Özet

Bu çalışma, dünyada en sık tüketilen psikoaktif madde ve santral sinir sistemi stimülanı olan kafeini tüm yönleriyle incelemektedir. Kakao, kahve çekirdeği, çay yaprakları ve guarana gibi bitkilerde doğal olarak bulunan kafein; gazlı/enerji içecekleri, analjezik ilaçlar ve sporcu takviyelerinde de yer almaktadır. Oral alımdan 45 dakika sonra gastrointestinal sistemden emilerek kan-beyin bariyeri ve plasentayı kolayca geçen kafein, temel olarak karaciğerde CYP1A2 enzimi aracılığıyla paraksantin, teofilin ve teobromin gibi metabolitlere dönüştürülüp böbrekler yoluyla atılır. Etkisini esasen adenozin reseptörlerinin kompetetif antagonizması üzerinden gösteren kafein, düşük dozlarda uyanıklık ve konsantrasyon artışı sağlarken; 400 mg üzerindeki günlük tüketimlerde anksiyete, insomni ve taşikardiye, 10 gram ve üzerindeki dozlarda ise ölüme yol açabilmektedir. Baş ağrısı ve neonatal apne gibi tıbbi endikasyonları bulunan madde, duyarlılığı artan adenozin reseptörleri nedeniyle fiziksel bağımlılık ve kesilme durumunda şiddetli baş ağrısı, yorgunluk gibi yoksunluk belirtileri oluşturabilir. Yasal, ucuz ve erişilebilir olması sebebiyle adli toksikoloji ile acil servis yönetimi açısından kritik önem taşıyan kafeinin kullanımıyla ilgili ülkemizde henüz özel bir yasal düzenleme bulunmamaktadır.

Referanslar

Fredholm BB. Notes on the history of caffeine use. [Online] Handbook of Experimental Pharmacology. Springer, Berlin, Heidelberg; 2011. p. 1–9. doi:10.1007/978-3-642-13443-2_1

Cauli O, Morelli M. Caffeine and the dopaminergic system. Behavioural Pharmacology. 2005;(16): 63–77. https://journals.lww.com/behaviouralpharm/Fulltext/2005/03000/Caffeine_and_the_dopaminergic_system.1.aspx

an Dam RM, Hu FB, Willett WC. Coffee, Caffeine, and Health. Campion EW (ed.) New England Journal of Medicine. Massachusetts Medical Society; 2020;383(4): 369–378. doi:10.1056/nejmra1816604

Humans IWG on the E of CR to. Caffeine. [Online] IARC monographs on the evaluation of carcinogenic risks to humans / World Health Organization, International Agency for Research on Cancer. International Agency for Research on Cancer; 1991. p. 291–390. https://www.ncbi.nlm.nih.gov/books/NBK507027/

Temple JL, Bernard C, Lipshultz SE, et al. The Safety of Ingested Caffeine: A Comprehensive Review. Frontiers in Psychiatry. Frontiers Media SA; 2017;8: 80. doi:10.3389/fpsyt.2017.00080

Heckman MA, Weil J, de Mejia EG. Caffeine (1, 3, 7-trimethylxanthine) in foods: A comprehensive review on consumption, functionality, safety, and regulatory matters. Journal of Food Science. John Wiley & Sons, Ltd; 2010;75(3): R77–R87. doi:10.1111/j.1750-3841.2010.01561.x

Desbrow B, Hall S, O’Connor H, et al. Caffeine content of pre-workout supplements commonly used by Australian consumers. Drug Testing and Analysis. John Wiley and Sons Ltd; 2019;11(3): 523–529. doi:10.1002/dta.2501

Hammad S, Tayyem R, Musaiger AO. Caffeine content in beverages commonly consumed in Jordan. Pakistan Journal of Nutrition. Asian Network for Scientific Information; 2015;14(8): 447–452. doi:10.3923/pjn.2015.447.452

DRUGDEX. Caffeine- In-Depth Answers - Dosing/Administration. [Online] IBM Micromedex [Electronic version]; www.micromedexsolutions.com

Ashihara H, Sano H, Crozier A. Caffeine and related purine alkaloids: Biosynthesis, catabolism, function and genetic engineering. [Online] Phytochemistry. Pergamon; 2008. p. 841–856. doi:10.1016/j.phytochem.2007.10.029

Research I of M (US) C on MN. Pharmacology of Caffeine. National Academies Press (US); 2001; https://www.ncbi.nlm.nih.gov/books/NBK223808/

DRUGDEX. Caffeine - In-Depth Answers - Pharmacokinetics. [Online] https://www.micromedexsolutions.com/

Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacological Reviews. American Society for Pharmacology and Experimental Therapy; 2018;70(2): 384–411. doi:10.1124/pr.117.014407

Burdan F. Pharmacology of Caffeine: The Main Active Compound of Coffee. Coffee in Health and Disease Prevention. Elsevier Inc.; 2015. p. 823–829. doi:10.1016/B978-0-12-409517-5.00090-5

Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: Influence of environmental factors and genetic polymorphisms. [Online] Pharmacogenomics. Future Medicine Ltd London, UK ; 2008. p. 625–637. doi:10.2217/14622416.9.5.625

O’Brien CP. Drug Use Disorders and Addiction. In: Brunton LL, Hilal-Dandan R, Knollmann BC (eds.) Goodman&Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. Mc Graw Hill Education; 2017. p. 433–442.

Holstege A, Kurz M, Weinbeck M, et al. Excretion of caffeine and its primary degradation products into bile. Journal of Hepatology. J Hepatol; 1993;17(1): 67–73. doi:10.1016/S0168-8278(05)80523-9

Bonsignore A, Sblano S, Pozzi F, et al. A case of suicide by ingestion of caffeine. Forensic Science, Medicine, and Pathology. Humana Press Inc.; 2014;10(3): 448–451. doi:10.1007/s12024-014-9571-6

Sheth S, Brito R, Mukherjea D, et al. Adenosine receptors: Expression, function and regulation. [Online] International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI); 2014. p. 2024–2052. doi:10.3390/ijms15022024

Sun WC, Moore JN, Hurley DJ, et al. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-α by equine monocytes. Veterinary Immunology and Immunopathology. 2008;121(1–2): 91–100. doi:10.1016/j.vetimm.2007.08.011

Haskó G, Pacher P. A 2A receptors in inflammation and injury: lessons learned from transgenic animals . Journal of Leukocyte Biology. Wiley; 2008;83(3): 447–455. doi:10.1189/jlb.0607359

Li JM, Fenton RA, Wheeler HB, et al. Adenosine A(2a) receptors increase arterial endothelial cell nritric oxide. Journal of Surgical Research. Academic Press Inc.; 1998;80(2): 357–364. doi:10.1006/jsre.1998.5439

Ballesteros-Yáñez I, Castillo CA, Merighi S, et al. The role of adenosine receptors in psychostimulant addiction. [Online] Frontiers in Pharmacology. Frontiers Media S.A.; 2018. p. 985. doi:10.3389/fphar.2017.00985

Rogers PJ, Heatherley S V., Mullings EL, et al. Faster but not smarter: Effects of caffeine and caffeine withdrawal on alertness and performance. Psychopharmacology. Springer; 2013;226(2): 229–240. doi:10.1007/s00213-012-2889-4

Hodgson AB, Randell RK, Jeukendrup AE. The Metabolic and Performance Effects of Caffeine Compared to Coffee during Endurance Exercise. PLoS ONE. PLoS One; 2013;8(4). doi:10.1371/journal.pone.0059561

Tunnicliffe JM, Erdman KA, Reimer RA, et al. Consumption of dietary caffeine and coffee in physically active populations: Physiological interactions. Applied Physiology, Nutrition and Metabolism. Appl Physiol Nutr Metab; 2008. p. 1301–1310. doi:10.1139/H08-124

Cappelletti S, Daria P, Sani G, et al. Caffeine: Cognitive and Physical Performance Enhancer or Psychoactive Drug? Current Neuropharmacology. Bentham Science Publishers Ltd.; 2014;13(1): 71–88. doi:10.2174/1570159x13666141210215655

Sweeney MM, Weaver DC, Vincent KB, et al. Prevalence and Correlates of Caffeine Use Disorder Symptoms Among a United States Sample. Journal of Caffeine and Adenosine Research. Mary Ann Liebert Inc; 2020;10(1): 4–11. doi:10.1089/caff.2019.0020

Cappelletti S, Piacentino D, Fineschi V, et al. Caffeine-related deaths: Manner of deaths and categories at risk. [Online] Nutrients. MDPI AG; 2018. doi:10.3390/nu10050611

Murray A, Traylor J. Caffeine Toxicity. [Online] StatPearls [Internet]. StatPearls Publishing; 2018. http://www.ncbi.nlm.nih.gov/pubmed/30422505

Hoffman RJ. Methylxanthines and Selective β2-Adrenergic Agonists. Goldfrank’s Toxicologic Emergencies. 10th ed. Mc Graw Hill Education; 2006. p. 999–1003. https://accessemergencymedicine.mhmedical.com/content.aspx?bookid=1163&sectionid=65096867

Rybak ME, Sternberg MR, Pao CI, et al. Urine excretion of caffeine and select caffeine metabolites is common in the US population and associated with caffeine intake. Journal of Nutrition. American Society for Nutrition; 2015;145(4): 766–774. doi:10.3945/jn.114.205476

Crews HM, Olivier L, Wilson LA. Urinary biomakers for assessing dietary exposure to caffeine. Food Additives and Contaminants. Food Addit Contam; 2001;18(12): 1075–1087. doi:10.1080/02652030110056630

Jain S, Srivastava AS, Verma RP, et al. Caffeine addiction: Need for awareness and research and regulatory measures. [Online] Asian Journal of Psychiatry. Elsevier B.V.; 2019. p. 73–75. doi:10.1016/j.ajp.2017.01.008

World Health Organization. The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. [Online] 1992. https://apps.who.int/iris/handle/10665/37958

Addicott MA. Caffeine Use Disorder: A Review of the Evidence and Future Implications. [Online] Current Addiction Reports. Springer; 2014. p. 186–192. doi:10.1007/s40429-014-0024-9

Meredith SE, Juliano LM, Hughes JR, et al. Caffeine Use Disorder: A Comprehensive Review and Research Agenda. Journal of Caffeine Research. Mary Ann Liebert Inc; 2013;3(3): 114–130. doi:10.1089/jcr.2013.0016

Nehlig A. Are we dependent upon coffee and caffeine? A review on human and animal data. [Online] Neuroscience and Biobehavioral Reviews. Neurosci Biobehav Rev; 1999. p. 563–576. doi:10.1016/S0149-7634(98)00050-5

Hasin DS, O’Brien CP, Auriacombe M, et al. DSM-5 criteria for substance use disorders: Recommendations and rationale. [Online] American Journal of Psychiatry. American Psychiatric Association; 2013. p. 834–851. doi:10.1176/appi.ajp.2013.12060782

Hackett PH. Caffeine at high altitude: Java at base camp. [Online] High Altitude Medicine and Biology. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA ; 2010. p. 13–17. doi:10.1089/ham.2009.1077

Morelli M, Simola N. Methylxanthines and drug dependence: A focus on interactions with substances of abuse. [Online] Handbook of Experimental Pharmacology. Handb Exp Pharmacol; 2011. p. 483–507. doi:10.1007/978-3-642-13443-2_20

Sigmon SC, Herning RI, Better W, et al. Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: Cerebral blood flow velocity, quantitative EEG, and subjective effects. Psychopharmacology. NIH Public Access; 2009;204(4): 573–585. doi:10.1007/s00213-009-1489-4

Yayınlanan

4 Kasım 2021

Lisans

Lisans